Research programme: HBV cccDNA formation inhibitors - Arbutus Biopharma

Drug Profile

Research programme: HBV cccDNA formation inhibitors - Arbutus Biopharma

Alternative Names: ARB-199; ARB-596; cccDNA formation inhibitors - Arbutus; Covalently closed circular DNA formation inhibitors - Arbutus

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
  • Developer Arbutus Biopharma; Baruch S. Blumberg Institute
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
  • 19 Nov 2014 OnCore Biopharma and Baruch S Blumberg Institute enter into a research collaboration to develop treatments for Hepatitis B and Liver cancer
  • 01 Feb 2014 Early research in Hepatitis B in USA (PO) (Tekmira Pharmaceuticals 10-K, March 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top